Advanced Targeted Therapy & Surgical Care by Dr. Lovedeep Singh Chauhan
HER2-positive breast cancer is one of the most biologically distinct and previously aggressive subtypes of breast cancer. However, with the development of modern targeted therapies and advances in surgical oncology, outcomes today are dramatically better than they were even two decades ago. When diagnosed early and treated with a scientifically planned, multidisciplinary approach, many patients achieve long-term survival and even cure.
Under the care of Dr. Lovedeep Singh Chauhan, Consultant Surgical Oncologist at Max Super Speciality Hospital, Mohali, patients receive evidence-based, personalized treatment designed around tumor biology, stage, and individual health factors. This comprehensive guide explains everything you need to know about HER2-positive breast cancer—from diagnosis to advanced treatment strategies and long-term follow-up.
Understanding HER2-Positive Breast Cancer
HER2-positive breast cancer is defined by overexpression or amplification of the Human Epidermal Growth Factor Receptor 2 (HER2) gene. HER2 is a protein receptor located on the surface of breast cells. It normally helps regulate cell growth and repair. However, when too many HER2 receptors are present, cells grow and divide uncontrollably, leading to aggressive tumor behavior.
Approximately 15–20% of breast cancers are HER2-positive. Historically, this subtype was associated with higher recurrence rates and poorer survival. Today, with targeted biological therapy such as Trastuzumab and other HER2-directed agents, prognosis has significantly improved.
HER2 positivity is not something a person “inherits” in most cases. Instead, it is a molecular feature identified in the tumor tissue after biopsy and pathological testing.
Diagnostic Evaluation and HER2 Testing
Accurate diagnosis is the foundation of successful treatment. The evaluation typically begins with a clinical breast examination followed by imaging such as mammography and ultrasound. MRI may be recommended in selected patients for better tumor mapping.
A core needle biopsy is then performed to obtain tissue for histopathological examination. Once cancer is confirmed, the tumor sample undergoes receptor testing to determine:
- Estrogen receptor (ER) status
- Progesterone receptor (PR) status
- HER2 status
HER2 testing is performed using:
- Immunohistochemistry (IHC): Measures protein overexpression
- Fluorescence In Situ Hybridization (FISH): Detects gene amplification when IHC results are equivocal
HER2 results are classified as:
- 0 or 1+ → Negative
- 2+ → Equivocal (requires FISH confirmation)
- 3+ → Positive
Correct classification is critical because treatment decisions depend heavily on HER2 status.
Staging of HER2-Positive Breast Cancer
Staging determines the extent of disease and guides treatment planning. It is based on:
- Tumor size (T)
- Lymph node involvement (N)
- Presence of distant metastasis (M)
Investigations such as CT scans, PET-CT, or bone scans may be required for advanced stages.
Early-stage HER2-positive cancer (Stage I–II) has excellent survival outcomes with modern therapy. Even in locally advanced cases (Stage III), significant tumor shrinkage is often achieved before surgery. Metastatic HER2-positive breast cancer (Stage IV) is treatable, and patients can live many years with appropriate targeted therapy.
Modern Treatment of HER2-Positive Breast Cancer
Targeted Therapy – The Breakthrough
The introduction of Trastuzumab transformed the treatment landscape by blocking HER2 receptors and helping the immune system destroy cancer cells.
Other HER2-targeted therapies include:
- Pertuzumab
- T-DM1
These therapies may be given before surgery (neoadjuvant), after surgery (adjuvant), or in metastatic disease. Typically, treatment continues for one year in early-stage cases.
Chemotherapy
Chemotherapy is commonly combined with HER2-targeted agents. In early-stage disease, neoadjuvant chemotherapy helps reduce tumor size and may allow breast conservation.
Achieving a pathological complete response significantly improves long-term survival outcomes.
Surgery
Surgery remains a cornerstone of curative treatment. The approach depends on tumor size, response to therapy, and patient preference.
- Breast-conserving surgery (lumpectomy)
- Modified radical mastectomy
- Sentinel lymph node biopsy
Reconstruction options may be offered to restore body image and confidence.
Radiation Therapy
Radiation therapy is typically recommended after breast-conserving surgery and in certain post-mastectomy cases to reduce local recurrence.
It plays a crucial role in comprehensive cancer control.
Comprehensive HER2-Positive Breast Cancer Care by Dr. Lovedeep Singh Chauhan
Management of HER2-positive breast cancer requires precision, coordination, and expertise in both surgical and systemic oncology. Dr. Lovedeep Singh Chauhan, Consultant Surgical Oncologist at Max Super Speciality Hospital, Mohali, offers comprehensive breast cancer care based on international treatment guidelines.
With advanced training in oncologic surgery, Dr. Chauhan focuses on delivering oncologically safe procedures while preserving quality of life. His approach integrates tumor biology with surgical planning, ensuring that each patient receives individualized care.
Patients benefit from:
- Detailed tumor evaluation and staging
- Multidisciplinary tumor board discussions
- Neoadjuvant therapy planning coordination
- Breast-conserving and oncoplastic surgery
- Advanced axillary management
- Post-treatment surveillance and survivorship care
Every treatment plan is carefully explained, allowing patients and families to make informed decisions.
Personalized, Evidence-Based Treatment Planning
No two breast cancers are identical. HER2-positive disease can behave differently depending on hormone receptor status and stage. Treatment strategies are therefore customized.
Patients are guided through:
- Understanding pathology reports
- Interpreting HER2 results
- Evaluating surgical options
- Planning reconstruction when appropriate
- Monitoring cardiac function during targeted therapy
This structured, patient-centered approach reduces anxiety and improves treatment adherence.
When to Seek Expert Consultation
You should consult a surgical oncologist if:
HER2 3+ or Amplification
Advised Chemotherapy
Need Second Opinion
Recurrence After Treatment
Early expert involvement ensures optimal sequencing of therapy and better outcomes.
Frequently Asked Questions
Have a Question? Get In Touch
